Sulforaphane enhanced muscle growth by promoting lipid oxidation through modulating key signaling pathways

Rui Zhang, Su-Qin Chen, Feng Zhao, Wei Wang, Dayu Liu, Lin Chen, Ting Bai, Zhoulin Wu, Lili Ji, Jiamin ZhangBioscience 2024 · DOI

TL;DR

This study reveals that sulforaphane (SFN), a compound found in cruciferous vegetables, promotes skeletal muscle growth and improves lipid metabolism in mice. SFN treatment enhanced muscle fiber size and reduced fat accumulation by modulating key signaling pathways involved in lipid oxidation and protein synthesis.

What Problem Does This Paper Address?

Skeletal muscle plays a crucial role in both movement and overall metabolic health. Maintaining muscle mass and function is vital, especially as we age or face conditions like muscle wasting. While sulforaphane (SFN) is known for its antioxidant and anti-inflammatory properties, its specific impact on skeletal muscle metabolism, particularly the balance between lipid and protein metabolism, has not been fully elucidated. This paper aims to investigate how SFN, at doses relevant to dietary intake, influences skeletal muscle growth and the underlying molecular mechanisms, focusing on lipid and protein metabolism.

Methods

The researchers used a combination of in vivo experiments and high-throughput molecular analyses.

  • Animal Model: C57BL/6J mice were administered SFN daily for 8 weeks at two different doses (1 mg/kg and 3 mg/kg) or a control vehicle.
  • Physiological Measurements: Body weight was monitored weekly. Muscle tissue (Longissimus dorsi, LD) was collected for histological analysis (fiber diameter and cross-sectional area) and biochemical analysis (triglyceride and total cholesterol levels).
  • Transcriptomic Analysis (RNA-seq): RNA was extracted from pooled LD muscle samples of each group. RNA-seq was performed to identify differentially expressed genes (DEGs) between control and SFN-treated groups.
  • Bioinformatics Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on DEGs to identify enriched biological pathways.
  • Quantitative Real-Time PCR (qRT-PCR): The expression levels of selected DEGs were validated using qRT-PCR to confirm RNA-seq findings.
  • Protein-Protein Interaction (PPI) Analysis: The STRING database was used to construct a PPI network for selected DEGs to understand potential functional and physical interactions between proteins involved in lipid and protein metabolism.

Datasets

The RNA-seq data generated in this study has been deposited in the China National GeneBank (https://db.cngb.org) with the accession number CNP0005235. No new benchmarks were introduced.

Key Insights and Ideas

  • Dietary-Relevant Doses Matter: The study demonstrates that SFN, even at relatively low, potentially dietary-relevant doses, can significantly impact skeletal muscle. This is important because higher doses are often used in research, which may not reflect real-world consumption.
  • SFN Promotes Lipid Oxidation: A key finding is that SFN enhances lipid oxidation, particularly through peroxisomal and mitochondrial pathways. This suggests SFN helps the muscle utilize fat for energy more effectively.
  • Balancing Lipid Synthesis and Breakdown: SFN appears to both promote fatty acid breakdown (oxidation) and inhibit fatty acid synthesis, leading to reduced lipid accumulation in muscle tissue.
  • Modulation of Key Metabolic Pathways: SFN's effects are mediated through the modulation of critical signaling pathways like AMPK (energy expenditure), PPAR (fatty acid metabolism), and peroxisome pathways.
  • Synergistic Effects on Muscle Growth: Beyond lipid metabolism, SFN also influences protein turnover pathways, including TGF-β and mTOR signaling, contributing to enhanced muscle fiber size.

Key Results

  • Increased Body Weight: Both SFN doses led to accelerated body weight increment compared to the control group.
  • Muscle Hypertrophy: The higher SFN dose (3 mg/kg) significantly increased the cross-sectional area and diameter of LD muscle fibers.
  • Reduced Lipid Content: Triglyceride (TG) and total cholesterol (TC) levels in LD muscle were significantly reduced in both SFN-treated groups.
  • Transcriptomic Changes: RNA-seq identified 2455 DEGs in the SFN1 group and 2318 DEGs in the SFN3 group compared to controls.
  • Enriched Pathways: GO and KEGG analyses revealed significant enrichment of pathways related to lipid metabolism (fatty acid, cholesterol, peroxisome), energy metabolism (AMPK), and muscle growth (TGF-β, mTOR).
  • qRT-PCR Validation: Gene expression changes observed in RNA-seq were confirmed by qRT-PCR for selected genes.

Limitations and Future Work

  • Mechanism of mTOR Regulation: The study notes contradictory findings in the literature regarding SFN's effect on mTOR signaling (suppression vs. restoration). Further detailed investigation is needed to clarify SFN's precise role in mTOR signaling in skeletal muscle.
  • Complement and Coagulation Cascades: The enrichment of the complement and coagulation cascades pathway in the SFN1 group, while interesting and potentially linked to muscle atrophy alleviation, warrants further exploration to understand its specific role in SFN's effects.
  • Long-Term Effects: The study was conducted over 8 weeks. Investigating the long-term effects of SFN supplementation on skeletal muscle health and function would be valuable.
  • Human Translation: While the study uses mouse models, further research in human subjects is necessary to confirm these findings and establish optimal SFN supplementation strategies for muscle health.

Summary updated

Abstract

Sulforaphane (SFN) has shown diverse effects on human health and diseases. SFN was administered daily to C57BL/6J mice at doses of 1 mg/kg (SFN1) and 3 mg/kg (SFN3) for 8 weeks. Both doses of SFN accelerated body weight increment. The cross-sectional area and diameter of Longissimus dorsi (LD) muscle fibers were enlarged in SFN3 group. Triglyceride (TG) and total cholesterol (TC) levels in LD muscle were decreased in SFN groups. RNA sequencing results revealed that 2455 and 2318 differentially expressed genes (DEGs) were found in SFN1 and SFN3 groups, respectively. Based on GO enrichment analysis, 754 and 911 enriched GO terms in the SFN1 and SFN3 groups, respectively. KEGG enrichment analysis shown that one KEGG pathway was enriched in the SFN1 group, while six KEGG pathways were enriched in the SFN3 group. The expressions of nine selected DEGs validated with qRT-PCR were in line with the RNA sequencing data. Furthermore, SFN treatment influenced lipid and protein metabolism related pathways including AMPK signaling, fatty acid metabolism signaling, cholesterol metabolism signalling, PPAR signaling, peroxisome signaling, TGFβ signaling, and mTOR signaling. In summary, SFN elevated muscle fibers size and reduced TG and TC content of in LD muscle by modulating protein and lipid metabolism-related signaling pathways.
BibTeX
@inproceedings{zhang2024sulforaphane,
  author = {Rui Zhang and Su-Qin Chen and Feng Zhao and Wei Wang and Dayu Liu and Lin Chen and Ting Bai and Zhoulin Wu and Lili Ji and Jiamin Zhang},
  title = {{Sulforaphane enhanced muscle growth by promoting lipid oxidation through modulating key signaling pathways}},
  booktitle = {Bioscience},
  year = {2024},
  doi = {10.1042/bsr20240084},
}
Figure